// App-Quantinova.ai

307 : Reduction in Structural Damage Progression and Improvement in Clinical Response with Abatacept Treatment in Patients with ACPA+, Early RA: Results from a Post Hoc Analysis of the AVERT-2 Study by Baseline Erosion Scores

Researchers

Presenter

  • Chahin Pachai

Principal Investigators

  • Sean E Connolly

  • Yoshiya Tanaka

  • Vivian Bykerk

  • Tom Huizinga

  • Gustavo Citera

  • Clifton O. Bingham III

  • Shuyan Du

  • Godehard Hoexter

  • Roy Fleischmann

  • Subhashis Banerjee

  • Paul Emery

Medical Centers

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Bristol-Myers Squibb, Morrisville, PA

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Hospital for Special Surgery, New York, NY.

  • Leiden University Medical Centre, Leiden, Netherlands

  • Instituto de Rehabilitaciόn Psicofísica (IREP), Buenos Aires

  • Johns Hopkins University, Baltimore, MD

  • Bristol Myers Squibb GmbH & Co. KGaA, Munich, Germany

  • Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX

Locations

  • United States

  • Japan

  • Netherlands

  • Argentina

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

  • Albumin/creatinine

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02504268

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved